Literature DB >> 20938384

Salmonella spondylodiscitis in the immunocompetent: our experience with eleven patients.

Rohit Amritanand1, K Venkatesh, Gabriel D Sundararaj.   

Abstract

STUDY
DESIGN: Retrospective case series.
OBJECTIVE: To report the clinical features, diagnostic dilemmas and management options of 11 immunologically normal patients with salmonella spondylodiscitis. SUMMARY OF BACKGROUND DATA: Majority of existing data on salmonella spondylodiscitis in the immunologically normal patient is from anecdotal case report.
METHODS: From 1995 to 2008, 11 patients with salmonella spondylodiscitis proven by positive culture, biopsy, and Widal test were included. One patient died, and the average follow-up of the remaining 10 patients was 36 months (12-122 months). Five (50%) patients had a documented history of typhoid fever. Intravenous antibiotics for 2 weeks and oral antibiotics for at least 10 weeks were given to all patients. Indications for surgical intervention were unrelenting pain and osseous instability. Clinical outcome was evaluated according to Macnab criteria.
RESULTS: Salmonella typhi was cultured in 4 and S. Paratyphi in 5 patients. No organism was identified in 2 patients, on whom the diagnosis was performed by a characteristic history, high Widal titers, and a positive biopsy. Widal titers were positive for all patients (Average + 1360). Five patients were managed with antibiotics only, 1 with surgical debridement and uninstrumented fusion and 4 with single-stage debridement, anterior fusion, and posterior instrumentation. Healing of disease with a good to excellent outcome was seen in all patients.
CONCLUSION: Salmonella and tuberculous spondylitis must be differentiated as they both have similar epidemiological and clinicoradiologic presentations. Prodromal gastrointestinal symptoms are usually not present. The diagnosis rests largely on the recovery of the organism by appropriate culture techniques. However, when this is not apparent the Widal test, in the setting of a suggestive history and radiograph, may be used as a diagnosis tool. Though antibiotics are the mainstay of treatment, surgical debridement with the use of instrumentation may be indicated in selected patients.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20938384     DOI: 10.1097/BRS.0b013e3181e87afe

Source DB:  PubMed          Journal:  Spine (Phila Pa 1976)        ISSN: 0362-2436            Impact factor:   3.468


  8 in total

1.  Spondylodiscitis in a 54-year-old female scuba diver.

Authors:  Neil Tuttle; Alexandra Brelis; Rachel Brereton; Kerrie Evans
Journal:  BMJ Case Rep       Date:  2018-03-28

2.  A case of canine discospondylitis and epidural empyema due to Salmonella species.

Authors:  Ioannis N Plessas; Philip Jull; Holger A Volk
Journal:  Can Vet J       Date:  2013-06       Impact factor: 1.008

3.  Salmonella spondylodiscitis of the thoracic vertebrae mimicking spine tuberculosis.

Authors:  Ferdhany Muhamad Effendi; Mohd Ikraam Ibrahim; Mohd Fairudz Mohd Miswan
Journal:  BMJ Case Rep       Date:  2016-07-05

4.  Fever of unknown origin in a patient initially presenting with traveller's diarrhoea.

Authors:  Malik Asif Humayun; Tristan Richardson; Augustin Brooks
Journal:  BMJ Case Rep       Date:  2016-09-30

5.  A special case of lower back pain in a 3-year-old girl.

Authors:  Davide Tassinari; Sara Forti; Michele Torella; Giovanni Tani
Journal:  BMJ Case Rep       Date:  2013-03-07

6.  Literature review and clinical presentation of cervical spondylitis due to salmonella enteritidis in immunocompetent.

Authors:  Zhi-Yun Feng; Fang Guo; Zhong Chen
Journal:  Asian Spine J       Date:  2014-04-08

7.  Thoracic spinal osteomyelitis due to Salmonella enteritidis in an immunocompetent mimicking tuberculosis.

Authors:  K Lakshmi; R Santhanam
Journal:  J Neurosci Rural Pract       Date:  2016 Apr-Jun

Review 8.  Salmonella enteritis spondylitis of thoracic spine: a case report and review of the literature.

Authors:  Mengmeng Chen; Ruideng Wang; Jianlin Shan; Hai Tang
Journal:  BMC Surg       Date:  2020-08-07       Impact factor: 2.102

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.